Search
Hydrocortisone phosphate
go.drugbank.com/drugs/DB14542ApprovedInvestigationalVet approvedCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, b...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPrednisolone hemisuccinate
go.drugbank.com/drugs/DB14633InvestigationalCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalEtrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub … [A261826] In fact, it has been observed that antigen-activated T cells within peripheral lymphoid organs can transiently downregulate S1P receptor levels to facilitate immune cells trafficking into the
Categories: Sphingosine-1-phosphate (S1P) receptor modulators, Cytochrome P-450 SubstratesEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigationalNon-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Ensar...
Categories: P-glycoprotein substratesCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.[FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into...
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalDaridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. … [L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Categories: P-glycoprotein substratesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmu...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 an...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates